 MINNEAPOLIS, Jan. 12, 2021 GLOBE NEWSWIRE -- Predictive Oncology Inc. NASDAQ: POAI Predictive Oncology or the Company, a knowledge-driven company focused on applying artificial intelligence AI to personalized medicine and drug discovery, today announced the closing of its previously announced registered direct offering of 3,650,840 shares of its common stock, at a purchase price of 0.842 per share, which was priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering were 3.074 million, before deducting the placement agents fees and other offering expenses payable by the Company. In a concurrent private placement, the Company also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,825,420 shares of common stock at an exercise price of 0.80 per share. 